Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: Pharmacokinetic, safety, and efficacy phase i clinical study

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 371-379

  Donders, Gilbert ^a,b   Neven, Patrick ^c   Moegele, Maximilian ^d   Lintermans, Anneleen ^c   Bellen, Gert ^b   Prasauskas, Valdas ^e   Grob, Philipp ^e   Ortmann, Olaf ^d   Buchholz, Stefan ^d  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Femicare vzw   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e Medinova Ltd   (Switzerland)

Author keywords

Aromatase inhibitors; Breast cancer; Lactobacilli; Vaginal atrophy; Vaginal estriol

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; AROMATASE INHIBITOR; ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE; FOLLITROPIN; GYNOFLOR; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; UNCLASSIFIED DRUG; TABLET;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LACTOBACILLUS ACIDOPHILUS; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MASS FRAGMENTOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTICENTER STUDY; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VAGINA ATROPHY; ATROPHY; BLOOD; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; INTRAVAGINAL DRUG ADMINISTRATION; MICROBIOLOGY; PATHOLOGY; TABLET; TREATMENT OUTCOME; VAGINA;

ADMINISTRATION, INTRAVAGINAL; AROMATASE INHIBITORS; ATROPHY; BREAST NEOPLASMS; ESTRADIOL; ESTRIOL; FEMALE; HUMANS; LACTOBACILLUS ACIDOPHILUS; MIDDLE AGED; POSTMENOPAUSE; TABLETS; TREATMENT OUTCOME; VAGINA;

EID: 84901689661     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2930-x     Document Type: Article

References (49)

1. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348(24):2431-2442 (Pubitemid 36682823)
2. Crandall C, Petersen L, Ganz PA, Greendale GA (2004) Association of breast cancer and its therapy with menopause-related symptoms. Menopause 11(5):519-530 (Pubitemid 40362150)
3. Donders GG, Vereecken A, Bosmans E, Dekeersmaecker A, Salembier G, Spitz B (2002) Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: Aerobic vaginitis. BJOG 109(1):34-43 (Pubitemid 37329321)
4. Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V (2008) Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 19(10):1669-1680
5. Ponzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P (2005) Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer 41(17):2673-2681 (Pubitemid 41607558)
6. Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M (2008) Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 13(3):222-231 (Pubitemid 351679897)
7. Cardozo L, Benness C, Abbott D (1998) Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. Br J Obstet Gynaecol 105(4):403-407 (Pubitemid 28237866)
8. Suckling J, Lethaby A, Kennedy R (2006) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 4:CD001500
9. Bygdeman M, Swahn ML (1996) Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 23:259-263 (Pubitemid 26000605)
10. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM Jr et al (1997) Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 15(3):969-973 (Pubitemid 27106279)
11. Nachtigall LE (1994) Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 61(1):178-180 (Pubitemid 24030700)
12. Kendall A, Dowsett M, Folkerd E, Smith I (2006) Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17(4):584-587
13. Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J et al (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100(7):475-482
14. Holmberg L, Anderson H (2004) HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet 363(9407):453-455 (Pubitemid 38210063)
15. Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M et al (2010) Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: A preliminary study. Gynecol Endocrinol 26:404-412
16. Labrie F, Cusan L, Gomez JL, Cote I, Berube R, Belanger P et al (2009) Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 16(1):30-36
17. Notelovitz M, Funk S, Nanavati N, Mazzeo M (2002) Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 99(4):556-562 (Pubitemid 34246288)
18. Santen RJ, Pinkerton JV, Conaway M, Ropka M, Wisniewski L, Demers L et al (2002) Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 9(3):179-187 (Pubitemid 34492326)
19. Al-Baghdadi O, Ewies AA (2009) Topical estrogen therapy in the management of postmenopausal vaginal atrophy: An up-to-date overview. Climacteric 12(2):91-105
20. Moegele M, Buchholz S, Seitz S, Ortmann O (2012) Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet 285:1397-1402
21. Mariani L, Gadducci A, Vizza E, Tomao S, Vici P (2013) Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy. Gynecol Endocrinol 29(1):25-29
22. Del PL (2012) Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients. Gynecol Endocrinol 28(9):740-745
23. Chollet JA (2009) Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis. Menopause 16:978-983
24. Donders GG, Van BB, Van de WP, Kaiser RR, Pohlig G, Gonser S et al (2010) Effect of lyophilized lactobacilli and 0.03 mg estriol (Gynoflor(R)) on vaginitis and vaginosis with disrupted vaginal microflora: A multicenter, randomized, single-blind, active-controlled pilot study. Gynecol Obstet Invest 70(4):264-272
25. Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P, Tuncay G (2005) The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. BJOG 112(2):234-240 (Pubitemid 40188254)
26. Kanne B, Patz B, Wackerle L (1986) Local treatment of vaginal infections with Doederlein bacteria and estriol in climacterium and senium. Frauenarzt 3:35-40
27. Kanne B (1989) Local administration of weakly dosed estriol and active Lactobacillus acidophilus in the postmenopausal period. Arch Gynecol Obstet 246(Supplement):134
28. Kanne B, Jenny J (1991) Local administration of low-dosed estriol and viable Lactobacillus acidophilus in the post-menopausal period. Gynäkol Rundsch 31(1):7-13
29. Jaisamrarn U, Triratanachat S, Chaikittisilpa S, Grob P, Prasauskas V, Taechakraichana N (2013) Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy. Climacteric 16(3):347-355
30. Kaiser RR, Michael-Hepp J, Weber W, Graf F, Lauritzen C (2000) Absorption of estriol from vaginal tablets after single and repeated application in healthy, postmenopausal women. Therapiewoche 3:2-8
31. Donders GG, Caeyers T, Tydhof P, Riphagen I, Van den Bosch T, Bellen G (2007) Comparison of two types of dipsticks to measure vaginal pH in clinical practice. Eur J Obstet Gynecol Reprod Biol 134(2):220-224 (Pubitemid 47451587)
32. Donders GG (1999) Microscopy of the bacterial flora on fresh vaginal smears. Infect Dis Obstet Gynecol 7(4):177-179
33. Donders GG (2007) Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol 21(3):355-373 (Pubitemid 46838566)
34. Lonning PE, Geisler J (2008) Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. J Steroid Biochem Mol Biol 108(3-5):196-202 (Pubitemid 351187920)
35. Blair IA (2010) Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future. Steroids 75(4-5):297-306
36. Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M et al (2012) Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 8(3):144-148
37. Keller PJ, Riedmann R, Fischer M (1980) Oestrone, oestradiol and oestriol content following intravaginal application of oestriol in the postmenopause. Gynäkol Rundsch 20:77-79
38. Mattsson L-A, Cullberg G (1983) A clinical evaluation of treatment with estriol vaginal cream versus suppository in postmenopausal women. Acta Obstet Gynecol Scand 62:397-401 (Pubitemid 14213524)
39. van Haaften M, Donker GH, Haspels AA, Thijssen JHH (1989) Oestrogen concentrations in plasma, endometrium, myometrium and vagina of postmenopausal women, and effects of vaginal oestriol (E3) and oestradiol (E2) applications. J Steroid Biochem 33(4A):647-653 (Pubitemid 19255742)
40. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS (2001) Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 93(10):754-762 (Pubitemid 32514798)
41. Dew JE, Wren BG, Eden JA (2003) A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 6(1):45-52 (Pubitemid 36398872)
42. Lyytinen H, Pukkala E, Ylikorkala O (2006) Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 108(6):1354-1360 (Pubitemid 44901007)
43. Head KA (1998) Estriol: safety and efficacy. Altern Med Rev 3(2):101-113 (Pubitemid 128709606)
44. van der Vies J (1982) The pharmacology of oestriol. Maturitas 4:291-299 (Pubitemid 13189099)
45. Anderson JN, Peck EJJ, Clark JH (1975) Estrogen-induced uterine responses and growth: relationship to receptor estrogen binding by uterine nuclei. Endocrinology 96:160-167
46. Heimer G, Englund D (1984) Estriol: Absorption after long-term vaginal treatment and gastrointestinal absorption as influenced by a meal. Acta Obstet Gynecol Scand 63:563-567 (Pubitemid 14018207)
47. Buhling KJ, Eydeler U, Borregaard S, Schlegelmilch R, Suesskind M (2012) Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. Arzneimittelforschung 62(8):378-383
48. Lattrich C, Stegerer A, Haring J, Schuler S, Ortmann O, Treeck O (2013) Estrogen receptor beta agonists affect growth and gene expression of human breast cancer cell lines. Steroids 78(2):195-202
49. Derzko C, Elliott S, Lam W (2007) Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 14(Suppl 1):S20-S40